A Comparative Study on the Level of Hepatic Steatosis and Fibrosis between Pre- and Post-Intravenous Chelation Therapy in Patients with Chronic Lead Poisoning.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20180904002

Enrollment

Registered

2018-09-04

Start date

2018-09-03

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic lead poisoning Hepatic steatosis Hepatic fibrosis Chronic lead poisoning Hepatotoxicity Hepatic steatosis Hepatic fibrosis Hepatitis Interleukin&#45

Interventions

Patients with chronic lead poisoning who hospitalized for intravenous chelation.

Basic Science

Patients with chronic lead poisoning

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Blood lead level equal to or above 70 mcg/dl Occupational lead exposure for more than 1 year

Exclusion criteria

Exclusion criteria: Viral hepatitis B or C Autoimmune hepatitis Wilson disease Hemochromatosis Significant alcohol consumption Diabetes Triglyceride level >200 mg/dL Waist circumference > 102 cm in men and > 88 cm in women Symptoms of acute lead poisoning Prior lead chelation therapy

Design outcomes

Primary

Measure	Time frame
Hepatic steatosis Before and after intravenously lead chelation CAP (Fibroscan),Hepatic fibrosis Before and after intravenously lead chelation Fibroscan	—

Secondary

Measure	Time frame
Liver function test Before and after intravenously lead chelation Blood chemistry test,Inflammatory mediators/ biomarkers Before and after intravenously lead chelation Blood test	—

Countries

Thailand

Contacts

Public ContactPIYAPAN PRUEKSAPANICH

King Chulalongkorn Memorial Hospital

mpkus1@gmail.com0867093746

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

A Comparative Study on the Level of Hepatic Steatosis and Fibrosis between Pre&#45; and Post&#45;Intravenous Chelation Therapy in Patients with Chronic Lead Poisoning.